Identification of Aspergillus fumigatus UDP-Galactopyranose Mutase Inhibitors

Julia S Martin Del Campo1, Meital Eckshtain-Levi1, Nancy J Vogelaar2

  • 1Department of Biochemistry, Virginia Tech, Blacksburg, VA, 24061, USA.

Scientific Reports
|September 9, 2017
PubMed

Insights

Researchers identified flavonoids, hesperetin and naringenin, as inhibitors of UDP-galactopyranose mutase (UGM), a key virulence factor in Aspergillus fumigatus. These compounds target the enzyme

Area of Science:

  • Mycology
  • Biochemistry
  • Medicinal Chemistry

Background:

  • Aspergillus fumigatus causes life-threatening invasive infections in immunocompromised individuals.
  • The fungal cell wall contains unique polysaccharides like galactofuran, making its biosynthesis enzymes potential therapeutic targets.
  • UDP-galactopyranose mutase (UGM) is a crucial enzyme in galactofuran synthesis and a significant virulence factor for A. fumigatus.

Purpose of the Study:

  • To discover novel inhibitors of A. fumigatus UGM by targeting its NADPH binding site.
  • To investigate the structure-activity relationships of flavonoid inhibitors against UGM.
  • To assess the impact of identified inhibitors on fungal cell wall biosynthesis and viability.

Main Methods:

  • High-throughput screening using an ADP-TAMRA probe to identify UGM inhibitors.
  • Enzyme inhibition assays to determine inhibitor potency (Ki values) against NADPH.
  • Synthesis and evaluation of UGM inhibitor derivatives to understand structure-activity relationships.
  • Congo red susceptibility assays and growth temperature studies to assess effects on fungal cell wall biosynthesis.

Main Results:

  • Flavonoids (2S)-hesperetin and (2S)-naringenin were identified as competitive inhibitors of UGM with Ki values of 6 µM and 74 µM, respectively.
  • The hydroxyl groups and phenyl-chroman moiety of (2S)-hesperetin were found to be critical for UGM inhibition.
  • The identified compounds demonstrated an impact on A. fumigatus cell wall biosynthesis.

Conclusions:

  • This study presents the first report of UGM inhibition in a eukaryotic human pathogen, A. fumigatus.
  • (2S)-hesperetin and (2S)-naringenin are promising lead compounds for developing new antifungal therapies targeting UGM.
  • Inhibiting UGM represents a viable strategy to disrupt A. fumigatus cell wall integrity and combat invasive infections.